Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
bortezomib
dexamethasone
multiple myeloma
phase I study
plitidepsin
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
23
06
2022
received:
30
03
2022
accepted:
02
08
2022
pubmed:
22
9
2022
medline:
3
3
2023
entrez:
21
9
2022
Statut:
ppublish
Résumé
Previous studies showed antitumor activity for plitidepsin plus dexamethasone (DXM) in relapsed/refractory multiple myeloma (r/r MM), and in vitro synergism with bortezomib (BTZ) or DXM against MM cells. This phase I trial evaluated plitidepsin (3-h intravenous infusion Day 1 and 15), BTZ (subcutaneous bolus Day 1, 4, 8, and 11), and DXM (orally Day 1, 8, 15, and 22), every 4 weeks in 36 r/r MM patients. Twenty-two patients were treated using a standard dose escalation design (10 at the recommended dose [RD] cohort), and 14 additional patients were treated to expand the RD cohort. No dose-limiting toxicities (DLTs) occurred during dose escalation. The highest dose level evaluated (plitidepsin 5.0 mg/m
Identifiants
pubmed: 36127823
doi: 10.1002/cam4.5250
pmc: PMC9972151
doi:
Substances chimiques
Bortezomib
69G8BD63PP
plitidepsin
Y76ID234HW
Dexamethasone
7S5I7G3JQL
Depsipeptides
0
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3999-4009Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Blood. 2013 Oct 3;122(14):2331-7
pubmed: 23950178
Blood. 2017 Nov 30;130(22):2392-2400
pubmed: 28847998
Blood. 2007 Nov 15;110(10):3557-60
pubmed: 17690257
Br J Haematol. 2013 Mar;160(5):649-59
pubmed: 23293914
Clin Cancer Res. 2010 Jun 15;16(12):3260-9
pubmed: 20530693
Blood. 2016 Feb 11;127(6):713-21
pubmed: 26631116
Drugs Today (Barc). 2020 May;56(5):337-347
pubmed: 32406881
Haematologica. 2008 Dec;93(12):1908-11
pubmed: 18768528
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
Drugs. 2018 Jan;78(1):19-37
pubmed: 29188449
Br J Haematol. 2015 Mar;168(6):820-3
pubmed: 25403264
Cancer Res. 2008 Jul 1;68(13):5216-25
pubmed: 18593922
Blood. 2013 Mar 14;121(11):1968-75
pubmed: 23319574
J Clin Oncol. 2010 May 1;28(13):2259-66
pubmed: 20368561
Blood. 2016 Jun 9;127(23):2833-40
pubmed: 27091875
Leukemia. 2014 May;28(5):981-92
pubmed: 24177258
Leukemia. 2017 Dec;31(12):2695-2701
pubmed: 28642620
N Engl J Med. 2003 Jun 26;348(26):2609-17
pubmed: 12826635
N Engl J Med. 2007 Nov 22;357(21):2123-32
pubmed: 18032762
N Engl J Med. 2007 Nov 22;357(21):2133-42
pubmed: 18032763
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
Curr Opin Oncol. 2006 Nov;18(6):598-608
pubmed: 16988581
Blood. 2014 Mar 6;123(10):1461-9
pubmed: 24429336
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Sci Rep. 2016 Oct 07;6:35100
pubmed: 27713531
Cancer. 2006 Mar 15;106(6):1316-9
pubmed: 16470606
Ann Hematol. 2019 Sep;98(9):2139-2150
pubmed: 31240472
Br J Haematol. 2004 Oct;127(2):165-72
pubmed: 15461622
N Engl J Med. 2019 Aug 22;381(8):727-738
pubmed: 31433920
Br J Haematol. 2016 Oct;175(2):252-264
pubmed: 27411022
Lancet Oncol. 2020 Feb;21(2):207-221
pubmed: 31859245
Cancer Med. 2023 Feb;12(4):3999-4009
pubmed: 36127823